Prescott Group Capital Management L.L.C. Has $4.19 Million Holdings in Codexis, Inc. $CDXS

Prescott Group Capital Management L.L.C. raised its position in Codexis, Inc. (NASDAQ:CDXS) by 304.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,568,359 shares of the biotechnology company’s stock after buying an additional 1,932,814 shares during the period. Prescott Group Capital Management L.L.C. owned 2.84% of Codexis worth $4,186,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CDXS. Millennium Management LLC boosted its position in Codexis by 3,376.5% in the third quarter. Millennium Management LLC now owns 4,067,559 shares of the biotechnology company’s stock valued at $9,925,000 after buying an additional 3,950,557 shares in the last quarter. Aberdeen Group plc boosted its position in Codexis by 94.7% in the fourth quarter. Aberdeen Group plc now owns 7,966,498 shares of the biotechnology company’s stock valued at $12,985,000 after buying an additional 3,874,436 shares in the last quarter. Opaleye Management Inc. boosted its position in Codexis by 32.6% in the second quarter. Opaleye Management Inc. now owns 12,600,000 shares of the biotechnology company’s stock valued at $30,744,000 after buying an additional 3,100,000 shares in the last quarter. Nantahala Capital Management LLC boosted its position in Codexis by 42.4% in the second quarter. Nantahala Capital Management LLC now owns 4,030,619 shares of the biotechnology company’s stock valued at $9,835,000 after buying an additional 1,200,000 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in shares of Codexis in the third quarter worth about $1,312,000. 78.54% of the stock is currently owned by institutional investors and hedge funds.

Codexis Trading Up 4.9%

CDXS opened at $2.58 on Thursday. The company has a debt-to-equity ratio of 0.94, a current ratio of 5.36 and a quick ratio of 5.23. The company has a market cap of $234.51 million, a price-to-earnings ratio of -6.97 and a beta of 2.52. The firm has a 50 day simple moving average of $2.16 and a 200 day simple moving average of $1.77. Codexis, Inc. has a fifty-two week low of $0.96 and a fifty-two week high of $3.87.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $15.25 million during the quarter, compared to the consensus estimate of $14.53 million. Codexis had a negative net margin of 40.97% and a negative return on equity of 68.09%. On average, sell-side analysts anticipate that Codexis, Inc. will post -0.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CDXS. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Codexis in a research note on Thursday, March 12th. Wall Street Zen downgraded shares of Codexis from a “buy” rating to a “hold” rating in a research note on Sunday, May 3rd. Weiss Ratings raised shares of Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Finally, Stifel Nicolaus set a $5.00 target price on shares of Codexis in a research note on Thursday, March 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.00.

Codexis Profile

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.